FDA enforcement records identify Greiner Bio-One North America, Inc. at 4238 Capital Drive, Monroe, North Carolina, as the recalling firm for VACUETTE LH Lithium Heparin Separator tubes under recall number Z-0200-2027, a Class II action reported on October 28, 2026. The affected article is catalog number 454008P, described as a 13 x 75 mm, 3.5 mL VACUETTE blood collection tube with lithium heparin and gel separator. The manufacturer's published product page lists the same item number with a green cap and yellow ring, non-ridged format, sterile presentation, and inner pack of 50 pieces. [1][2][3]

Documented product identity and configuration

The manufacturer's catalog entry for item 454008P describes a VACUETTE TUBE 3.5 mL LH Lithium Heparin Separator, 13x75, green cap with yellow ring, non-ridged, sterile, with an inner pack of 50 pieces. The same catalog page places the item within a heparin tube family that also lists LH Lithium Heparin, LH Lithium Heparin Sep, and NH Sodium Heparin variants, and the broader VACUETTE blood collection tube category spans coagulation sodium citrate/CTAD, serum, heparin, EDTA, no additive, glucose, and trace element subcategories. The catalog notes that not all products shown are available for sale in the United States. [3][4][6]

A product safety data sheet for the VACUETTE Tube LH Lithium Heparin Separator, version 1.3 valid from January 20, 2025, identifies the product's use as in-vitro diagnostic and names Greiner Bio-One GmbH in Kremsmünster, Austria, as the supplier of the safety data sheet. The VACUETTE evacuated blood collection system instructions for use, revision 24 dated May 2022, describe plastic tubes with a pre-defined vacuum for exact draw volumes, fitted with colour-coded safety caps, intended for the collection, transport, storage and processing of venous blood for serum, plasma or whole blood testing in the clinical laboratory, for professional use. [7][9]

Recall record for lot B26043FM

The FDA enforcement record for Z-0200-2027 states that lot B26043FM may include EDTA contamination which introduces potassium while chelating calcium in patient samples, leading to falsely elevated potassium and falsely decreased calcium results. The record lists the action as voluntary and firm-initiated, with recall initiation on July 29, 2026, center classification on October 21, 2026, and a report date of October 28, 2026, under Class II. The stated product quantity is 860,450, and the distribution pattern is described as U.S. nationwide in the states of CO, FL, IL, MO, NE, NY, OH, PA, and VA. [1]

The FDA recall database entry carries the title Class 2 Device Recall VACUETTE LH Lithium Heparin Separator Tubes. A distributor notice dated July 29, 2026, issued by Greiner Bio-One North America, Inc. from the Monroe, North Carolina address, is headed Recall 26-583: VACUETTE Lithium Heparin Blood Collection Tubes and states that the firm is voluntarily recalling the VACUETTE TUBE 3.5 ml product due to a potential quality issue. The notice identifies the initial firm notification as a letter. [2][5]

Regulatory filing context

An FDA 510(k) premarket notification record, K103041, shows a decision of substantially equivalent dated November 9, 2010, with clinical chemistry as the regulation medical specialty and review panel, a special type designation, no third-party review, and no combination product status. The record's page was last updated November 2, 2026. The linked portfolio snapshot for this company contains no linked records and no decision counts, so the collection does not establish a broader filing history for this applicant. [8]